Delayed platelet recovery, and attendant bleeding complications, is a major determinant of morbidity and mortality following myelosuppressive/myeloablatlve chemoradiotherapy. Hematopoiesis is critically dependent on the interplay of temporally expressed adhesion molecules that create relevant growth niches within the bone marrow. The stage-dependent display and function of distinct adhesion molecules is tightly controlled by hematopoietic cytokines and chemokines, which promote or inhibit hematopoietic stem cell (HSC) proliferation, differentiation, maturation and migration. These effects are mediated in part by modulation of cell surface lactosaminyl glycans, especially those containing terminal sialic acid and fucose modifications. Expression of these structures within hematopoietic marrow cells occurs in a stage-specific and lineage-specific fashion. In studies to date using mice deficient in the (pi,4)-galactosyltransferase, P4GalTl, we have obtained direct evidence that lactosaminyl glycans are key regulators of thrombopoiesis. In this project, we seek to define the distinct lactosaminyl glycans expressed on mouse and human megakaryocyte progenitors (MKPs) and megakaryocytes (MKs), and the pertinent protein scaffolds and lipids that present these glycans critical for thrombopoiesis. We will define the changes in surface lactosaminyl glycans induced by thrombopoletic chemokines and cytokines or bone marrow endothelial cells (BMECs), and examine how these lactosaminyl structures mediate adhesive interactions with BMECs critical to hematopoiesis in vitro and in vivo. To obtain knowledge translatable to practical therapeutic strategies, we will extend our studies to human cells to specifically determine how deficiency in p4GalT1 affects human thrombopoiesis and lactosaminoglycan surface expression. We will determine the pertinent protein scaffolds and lipids that present lactosaminoglycans critical for thrombopoiesis in human MKs and analyze the effects of chemokines and cytokines or BMECs on lactosaminoglycan expression. We will examine how changes in surface lactosaminoglycans on human MKs affect adhesive functions with BMECs in vitro and in vivo. These studies will address fundamental questions regarding the glycobiology of thrombopoiesis. We will also investigate the capacity of platelets to serve as mediators of extrinsic glycosylation. The generated information will serve to develop strategies to modulate expression of key terminal lactosaminyl glycans to enhance thrombopoiesis and platelet production following myelosuppressive/myeloablatlve chemoradiotherapy and in other conditions of thrombocytopenia, including bone marrow failure states.

Public Health Relevance

Bleeding complications following myelosuppressive/myeloablative chemoradiotherapy due to delayed platelet recovery are a major determinant of morbility and mortality. Increasing platelet production following myelosuppressive/myeloablative chemoradiotherapy will decrease the need for platelet transfusions and associated side effects, such as sepsis and antibody refractoriness to platelet transfusion.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Irons, Eric E; Lau, Joseph T Y (2018) Systemic ST6Gal-1 Is a Pro-survival Factor for Murine Transitional B Cells. Front Immunol 9:2150
Videira, Paula A; Silva, Mariana; Martin, Kyle C et al. (2018) Ligation of the CD44 Glycoform HCELL on Culture-Expanded Human Monocyte-Derived Dendritic Cells Programs Transendothelial Migration. J Immunol 201:1030-1043
Carrascal, Mylène A; Talina, Catarina; Borralho, Paula et al. (2018) Staining of E-selectin ligands on paraffin-embedded sections of tumor tissue. BMC Cancer 18:495
Mondal, Nandini; Dykstra, Brad; Lee, Jungmin et al. (2018) Distinct human ?(1,3)-fucosyltransferases drive Lewis-X/sialyl Lewis-X assembly in human cells. J Biol Chem 293:7300-7314
Donnelly, Conor; Dykstra, Brad; Mondal, Nandini et al. (2018) Optimizing human Treg immunotherapy by Treg subset selection and E-selectin ligand expression. Sci Rep 8:420
Carrascal, Mylène A; Silva, Mariana; Ramalho, José S et al. (2018) Inhibition of fucosylation in human invasive ductal carcinoma reduces E-selectin ligand expression, cell proliferation, and ERK1/2 and p38 MAPK activation. Mol Oncol 12:579-593
Silva, Mariana; Videira, Paula A; Sackstein, Robert (2017) E-Selectin Ligands in the Human Mononuclear Phagocyte System: Implications for Infection, Inflammation, and Immunotherapy. Front Immunol 8:1878
Manhardt, Charles T; Punch, Patrick R; Dougher, Christopher W L et al. (2017) Extrinsic sialylation is dynamically regulated by systemic triggers in vivo. J Biol Chem 292:13514-13520
Sackstein, Robert; Schatton, Tobias; Barthel, Steven R (2017) T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest 97:669-697
Silva, Mariana; Fung, Ronald Kam Fai; Donnelly, Conor Brian et al. (2017) Cell-Specific Variation in E-Selectin Ligand Expression among Human Peripheral Blood Mononuclear Cells: Implications for Immunosurveillance and Pathobiology. J Immunol 198:3576-3587

Showing the most recent 10 out of 69 publications